



(11) **EP 2 783 686 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Abstract

(51) Int Cl.:
A61K 31/4196 ^(2006.01) **A61K 31/436** ^(2006.01)
A61P 35/00 ^(2006.01) **A61K 31/337** ^(2006.01)
A61K 31/502 ^(2006.01) **A61K 31/704** ^(2006.01)
A61K 31/7068 ^(2006.01) **A61K 33/24** ^(2006.01)

(48) Corrigendum issued on:
04.03.2015 Bulletin 2015/10

(43) Date of publication:
01.10.2014 Bulletin 2014/40

(21) Application number: **14164259.5**

(22) Date of filing: **18.02.2002**

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
LT LV RO SI

(30) Priority: **19.02.2001 GB 0104072**
17.10.2001 GB 0124957

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
02719864.7 / 1 363 627

(71) Applicants:
• **Novartis AG**
4056 Basel (CH)
Designated Contracting States:
BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE TR
• **Novartis Pharma GmbH**
1230 Wien (AT)
Designated Contracting States:
AT

(72) Inventors:
• **Lane, Heidi**
4106 Therwill (CH)
• **O'Reilly, Terence**
4057 Basel (CH)
• **Wood, Jeanette Marjorie**
4105 Biel-Benken (CH)

(74) Representative: **Kristl, Jernej**
Novartis Pharma AG
Patent Department
4002 Basel (CH)

Remarks:

This application was filed on 10-04-2014 as a
divisional application to the application mentioned
under INID code 62.

(54) **Combination of a rapamycin derivative and letrozole for treating breast cancer**

(57) The disclosure relates to 40 0 (2 hydroxyethyl)
rapamycin in combination with letrozole for use in the
treatment of breast cancer.

EP 2 783 686 A8